The Journal of Targeted Therapies in Cancer

Our physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.
Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Soft tissue sarcomas are a rare and challenging group of malignancies of mesenchymal origin that have historically been treated with similar approaches.
Treating sensitizing EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) leads to better outcomes compared with standard chemotherapy.
It is estimated that 1 in 63 individuals in the United States will develop renal cell carcinoma (RCC), making it among the most common cancers in the country.
Hepatocellular cancer (HCC) is a rapidly fatal malignancy that is often diagnosed at an advanced stage when it is not curable. Despite a rise in incidence, this cancer is not as common in the Western world as it is in Asia and Africa.
Therapies targeted to tumor biology hold the promise of improved outcomes for patients with breast cancer.
JTT Articles
Immune Checkpoint Inhibitors for Renal Cell Carcinoma
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
External Resources

MJH Associates
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2015
Intellisphere, LLC. All Rights Reserved.